Food and Drug Administration Headquarters Consolidation at White Oak, Silver Spring, Maryland

FDA campus

Supplemental EIS for Master Plan Update 2008-2009

The U.S. General Services Administration (GSA) proposes to update the current approved Master Plan for the U.S. Food and Drug Administration (FDA) Headquarters Consolidation to accommodate growth from 7,720 to 8,889 employees.  The growth is needed to support the legislatively mandated expansion of the FDA Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee and Modernization Act (MDUFMA) programs.  Additional building(s) and infrastructure will be needed to accommodate the growth.

GSA is developing a Supplemental Environmental Impact Statement (SEIS) that will analyze a range of alternatives including a no action alternative for the proposed Master Plan update.  As part of the SEIS, GSA will study the impacts of each alternative on the human environment.

Public Involvement OpportunitiesScoping for the SEIS was conducted from March 7, 2008 through April 7, 2008.  Comments received during the scoping period were considered during the preparation of the Draft SEIS.  The Draft SEIS was made available for public comment from March 27, 2009 through May 11, 2009. A public hearing for the Draft SEIS was held on April 30, 2009, from 6:30 p.m. to 8:30 p.m., at the CHI Center (Multipurpose Room), located at 10501 New Hampshire Avenue, Silver Spring, Md.

The Final SEIS is being made available for a 30-day public comment period and can be downloaded from this site.  As part of the Final SEIS, GSA is also inviting comments on historic preservation concerns under Section 106 of the National Historic Preservation Act.

Comments may be submitted by mail or email during the 30-day review period.  The review period for this Final SEIS began on July 31, 2009 (date of the Federal Register publication of the notice of availability) and ends August 31, 2009.  Comments must be postmarked by August 31, 2009.  Please send all written comments to:

Suzanne Hill
General Services Administration
NCR/NEPA Lead
301 7th Street, SW
Room 7600
Washington, DC 20407
(202) 708-7671 Fax
suzanne.hill@gsa.gov

 Final FDA Headquarters Consolidation Plan Documents

FDA Headquarters Consolidation Master Plan Update Vol. I:
Final Supplemental Environmental Impact Statement (SEIS)

Appendix A. Threatened and Endangered Species Review

Appendix B. GSA and other agencies' Memo of Agreement, 7/2002

Appendix C. FDA White Oak Consolidation Project Master Plan Update - Air and Noise Quality Technical Report

Appendix D. FDA Transportation Management Plan

Appendix E. FDA Headquarters Consolidation Traffic Technical Report

Doc ID Name Format Size Publish Date
  Federal Register Notice of Intent PDF 53k 7/1/2008
  Scoping Meeting Brochure PDF 147k 7/1/2008
  Scoping Meeting Presentation PDF 2549k 7/1/2008
  FDA Master Plan Update Volume 1 PDF 7367k 4/17/2009
  FDA Master Plan Update Volume 2 PDF 23665k 4/17/2009
Last Reviewed 8/17/2009